| scholarly article | Q13442814 |
| P356 | DOI | 10.1210/EN.2008-1210 |
| P698 | PubMed publication ID | 19022889 |
| P2093 | author name string | Heather A Harris | |
| Barry S Komm | |||
| Judy S Crabtree | |||
| Richard C Winneker | |||
| Bryan J Peano | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | estrogen | Q277954 |
| P304 | page(s) | 1897-1903 | |
| P577 | publication date | 2008-11-20 | |
| P1433 | published in | Endocrinology | Q3054009 |
| P1476 | title | Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland | |
| P478 | volume | 150 |
| Q38149162 | Bazedoxifene + conjugated estrogens in HT for the prevention of osteoporosis and treatment of vasomotor symptoms associated with the menopause |
| Q30455905 | Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention |
| Q37698607 | Bazedoxifene: a novel selective estrogen receptor modulator for postmenopausal osteoporosis |
| Q30409045 | Breast-related effects of selective estrogen receptor modulators and tissue-selective estrogen complexes |
| Q44129390 | Carcinogenicity and hormone studies with the tissue-selective estrogen receptor modulator bazadoxifene |
| Q38192058 | Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy |
| Q52342343 | Effect of a tissue selective estrogen complex on breast cancer: Role of unique properties of conjugated equine estrogen. |
| Q37146858 | Effects of bazedoxifene acetate with and without conjugated equine estrogens on the breast of postmenopausal monkeys |
| Q44620640 | Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women |
| Q30353161 | Effects of the conjugated equine estrogen/bazedoxifene tissue-selective estrogen complex (TSEC) on mammary gland and breast cancer in mice |
| Q35092811 | Efficacy and safety of bazedoxifene for postmenopausal osteoporosis |
| Q38307019 | Emerging hormonal treatments for menopausal symptoms |
| Q37648048 | Endometriosis impairs bone marrow-derived stem cell recruitment to the uterus whereas bazedoxifene treatment leads to endometriosis regression and improved uterine stem cell engraftment |
| Q38077503 | Evolution of the tissue selective estrogen complex (TSEC). |
| Q51037034 | Genistein modulation of seizure: involvement of estrogen and serotonin receptors. |
| Q43715217 | Global profiling of TSEC proliferative potential by the use of a reporter mouse for proliferation. |
| Q33861798 | Glyceollins trigger anti-proliferative effects through estradiol-dependent and independent pathways in breast cancer cells |
| Q44341394 | Hot flush symptom-free days with bazedoxifene/conjugated estrogens in postmenopausal women |
| Q35092609 | Incorporating bazedoxifene into the treatment paradigm for postmenopausal osteoporosis in Japan |
| Q35885187 | Incorporating bazedoxifene/conjugated estrogens into the current paradigm of menopausal therapy |
| Q36174098 | Low doses of 17β-estradiol rapidly improve learning and increase hippocampal dendritic spines. |
| Q33789215 | Modulation of human estrogen receptor α activity by multivalent estradiol-peptidomimetic conjugates |
| Q27014775 | New antiresorptive therapies for postmenopausal osteoporosis |
| Q33714186 | Novel therapies targeting endometriosis |
| Q26825692 | Nuclear receptors and their selective pharmacologic modulators |
| Q26751149 | Patient considerations in the management of menopausal symptoms: role of conjugated estrogens with bazedoxifene |
| Q38102040 | Pharmacokinetic evaluation of bazedoxifene for the treatment of osteoporosis. |
| Q37808639 | Preventing osteoporosis with a tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens (BZA/CE) |
| Q37048294 | Profile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture |
| Q38123239 | Rapid oestrogenic regulation of social and nonsocial learning. |
| Q34490225 | Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast |
| Q48189748 | The Tissue-Selective Estrogen Complex (Bazedoxifene/Conjugated Estrogens) for the Treatment of Menopause. |
| Q35001394 | The conundrum of estrogen receptor oscillatory activity in the search for an appropriate hormone replacement therapy. |
| Q26827973 | The evolution of selective estrogen receptor modulators in osteoporosis therapy |
| Q38993271 | The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms |
| Q37277298 | The tissue selective estrogen complex: a promising new menopausal therapy |
| Q53837780 | Tissue selective estrogen complex (TSEC): a review. |
| Q30456770 | Tissue selective estrogen complex combinations with bazedoxifene/conjugated estrogens as a model |
| Q37801227 | Tissue-Selective Agents: Selective Estrogen Receptor Modulators and the Tissue-Selective Estrogen Complex |
| Q37768158 | Tissue-selective estrogen complexes: a promising option for the comprehensive management of menopausal symptoms |
| Q34271979 | Treating postmenopausal osteoporosis in women at increased risk of fracture - critical appraisal of bazedoxifene: a review |
| Q35110859 | Treatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse model |
Search more.